The estimated Net Worth of Thomas Kiley is at least $1.38 Миллион dollars as of 22 November 2011. Thomas Kiley owns over 64,275 units of Geron stock worth over $1,378,719 and over the last 22 years Thomas sold GERN stock worth over $0.
Thomas has made over 2 trades of the Geron stock since 2011, according to the Form 4 filled with the SEC. Most recently Thomas bought 64,275 units of GERN stock worth $100,269 on 22 November 2011.
The largest trade Thomas's ever made was buying 64,275 units of Geron stock on 22 November 2011 worth over $100,269. On average, Thomas trades about 6,014 units every 3 days since 2003. As of 22 November 2011 Thomas still owns at least 314,059 units of Geron stock.
You can see the complete history of Thomas Kiley stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is , , , , .
Over the last 21 years, insiders at Geron have traded over $2,393,273 worth of Geron stock and bought 340,678 units worth $567,384 . The most active insiders traders include John A Scarlett, Daniel Bradbury и Stephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of $587,812. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth $1,159,879.
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
Geron executives and other stock owners filed with the SEC include: